Pelvic Embolisation to Reduce Recurrent Varicose Veins - Recurrent
NCT ID: NCT01909024
Last Updated: 2014-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
270 participants
INTERVENTIONAL
2013-07-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pelvic Embolisation to Reduce Recurrent Varicose Veins - Primary
NCT01901731
Embolization of Pelvic Varicosities in Patients With Pelvic Congestion Syndrome
NCT03057067
RCT - Does Treating Incompetent Perforators Reduce Recurrence?
NCT01949207
Investigation Into the Pathophysiology and Treatment of Varicose Veins
NCT06192472
Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome
NCT02796092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The commonest causes of recurrence are reported to be:
* neovascularisation (new vessel growth after treatment)
* missing veins at the initial operation
* perforator vein incompetence
* de novo reflux due to normal deterioration with age
Recent studies have shown that leg varicose veins can be caused by pelvic venous reflux and that pelvic venous reflux is a cause of recurrent varicose veins. Previous published work from our own unit has shown that approximately 20% of women who present with varicose veins of the legs and who have had children previously have pelvic venous reflux on duplex ultrasound. Such pelvic venous reflux contributes to the venous reflux in the legs, causing the varicose veins. Furthermore, a recent retrospective study from our own unit has suggested that failure to treat pelvic venous reflux before treating leg varicose veins is a major cause of recurrent varicose veins in up to a quarter of women.
However, despite this circumstantial evidence, there is no evidence to prove whether the treatment of pelvic venous reflux confers any advantage on these patients in terms of reduction in future recurrence of their varicose veins, following treatment.
The treatment of pelvic venous reflux is currently by coil embolisation of the veins under x-ray control. This procedure clearly has an additional cost over and above that of treating the leg varicose veins alone. Therefore it is essential to know whether the treatment of the pelvic veins in these patients has any effect in reducing future recurrence of leg varicose veins.
To examine the benefits of coil embolisation, female patients presenting with recurrent leg varicose veins with a duplex proven contribution from pelvic venous reflux will be randomised to:
1. transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
or
2. endovenous treatment of leg recurrent varicose veins alone
The impact of demographic factors, the severity of patient's symptoms(Aberdeen questionnaire, CEAP and VCCS scores)and treatment history will be explored, in addition to the type of treatment received.
Patients will be followed up at six weeks, six months, one year, two years, three years, four years and five years.
Outcome measures will include quality-of-life scoring (CIVIQ), symptom severity measures (Aberdeen questionnaire, CEAP and VCCS scores), patient satisfaction with treatment and clinical examination including clinical photographs and duplex ultrasonography.
The source of any recurrence will be classified through the use of duplex ultrasonography.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
embolisation of pelvic veins & treatment of leg varicose veins
transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
Coil embolisation
transjugular coil embolisation of pelvic veins
endovenous treatment of leg recurrent varicose veins
endovenous treatment of leg recurrent varicose veins
endovenous treatment of leg recurrent varicose veins alone
endovenous treatment of leg recurrent varicose veins alone
endovenous treatment of leg recurrent varicose veins
endovenous treatment of leg recurrent varicose veins
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coil embolisation
transjugular coil embolisation of pelvic veins
endovenous treatment of leg recurrent varicose veins
endovenous treatment of leg recurrent varicose veins
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Duplex proven reflux in the superficial venous system of the leg
* Over 18 years old
* Able to understand and give consent
* Willing to attend for follow-up over the five years
Exclusion Criteria
* If pelvic venous reflux communicates and contributes to varicose veins in one leg but not the other, only the leg with a pelvic venous contribution will be entered into the study
* Currently pregnant or plans for pregnancy within the next five years
* Under 18 years of age
* Unable to understand all give consent
* Any vascular malformation of the pelvis all the legs apart from that diagnosed as venous reflux disease
* Any medical condition likely to cause death or serious ill-health within the next five years Any deep venous obstruction or reflux
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Whiteley Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Whiteley, Professor
Role: PRINCIPAL_INVESTIGATOR
The Whiteley Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Whiteley Clinic
Guildford, , United Kingdom
The Imaging Clinic
Guildford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tony Lopez, BSC, MRP, FRCR
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RCT23013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.